Sentian Bio

Sentian Bio is a preclinical-stage biotechnology company dedicated to developing novel, non-opioid therapeutics for the treatment of chronic and neuropathic pain. The company's approach focuses on modulating neuronal excitability by targeting specific ion channels, particularly A-type potassium channels, to restore normal signaling in the peripheral nervous system. By leveraging proprietary insights into the molecular mechanisms of sensory neuron plasticity, Sentian Bio identifies small molecules that can provide long-lasting relief without the central nervous system side effects typical of current treatments. Their lead research programs aim to address significant unmet needs in conditions such as post-herpetic neuralgia and diabetic neuropathy. Headquartered in St. Louis, the company utilizes a specialized screening platform to accelerate the discovery of highly selective pain-relieving candidates.